Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

NCT01306045 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

647

Enrollment

NIH

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell Lung
Carcinoma, Thymic

Interventions

DRUG: AZD6244
DRUG: MK-2206
DRUG: Lapatinib
DRUG: Erlotinib
DRUG: Sunitinib
PROCEDURE: Molecular Profiling

Sponsor

National Cancer Institute (NCI)